Brief: Synact Pharma Says Current Cash, Cash Equivalents Insufficient To Meet Co's Liquidity Needs Over Next 12 Months
Aug 20 (Reuters) - SynAct Pharma AB SYNACT.ST :
* CURRENT CASH, CASH EQUIVALENTS ARE INSUFFICIENT TO MEET
CO'S
LIQUIDITY NEEDS OVER NEXT 12 MONTHS
* BOARD EVALUATES VARIOUS FINANCIAL ALTERNATIVES INCLUDING
OPTIMAL
TIMING AND SIZE OF CAPITAL RAISE
* BOARD HAS POSITIVE VIEW OF BEING ABLE TO CARRY OUT SUCH
CAPITAL
FUNDING
Source text for Eikon: ID:nMFN2rsC67
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development